Amplify Weight Loss Drug & Treatment ETF (THNR)
| Assets | $4.14M |
| Expense Ratio | 0.59% |
| PE Ratio | 17.19 |
| Shares Out | 170,000 |
| Dividend (ttm) | $0.41 |
| Dividend Yield | 1.61% |
| Ex-Dividend Date | Dec 30, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 27.64% |
| Volume | 476 |
| Open | 25.65 |
| Previous Close | 25.69 |
| Day's Range | 25.65 - 25.65 |
| 52-Week Low | 21.70 |
| 52-Week High | 27.28 |
| Beta | 0.38 |
| Holdings | 23 |
| Inception Date | May 21, 2024 |
About THNR
Fund Home PageThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Top 10 Holdings
61.39% of assets| Name | Symbol | Weight |
|---|---|---|
| Novo Nordisk A/S | NVO | 9.91% |
| Eli Lilly and Company | LLY | 9.45% |
| Scholar Rock Holding Corporation | SRRK | 5.76% |
| Hims & Hers Health, Inc. | HIMS | 5.53% |
| Viking Therapeutics, Inc. | VKTX | 5.43% |
| AbbVie Inc. | ABBV | 5.30% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.01% |
| Merck & Co., Inc. | MRK | 5.01% |
| AstraZeneca PLC | AZN | 5.00% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 4.99% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.41317 | Dec 31, 2025 |
| Dec 30, 2024 | $0.2199 | Dec 31, 2024 |
Performance
THNR had a total return of 15.55% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.71%.
News
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
LLY Clears Major Obesity Trial: Get Exposure in THNR
Weight loss drugs have been a big growth area in pharmaceuticals since GLP-1s hit the scene. This booming market has also breathed new life into companies like Eli Lilly (LLY), turning the stock into ...
SILJ, HACK, THNR: Trends in Thematic Investing
Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.